Drug Safety

, Volume 31, Issue 11, pp 1017–1026 | Cite as

Serious Adverse Reactions of Bupropion for Smoking Cessation

Analysis of the French Pharmacovigilance Database from 2001 to 2004
  • Marie-Nöelle Beyens
  • Claire Guy
  • Genevieve Mounier
  • Sylvie Laporte
  • Michel Ollagnier
Original Research Article


Background: Bupropion was the first alternative to nicotine replacement therapy in the pharmacological treatment for smoking cessation. Its safety profile has been monitored in France via spontaneous reporting.

Objective: To describe all serious adverse reactions (SARs) reported in France since the marketing authorization for bupropion in September 2001, and to analyse risk factors for these SARs.

Design: We collected all spontaneous reports of adverse reactions to bupropion received by all French Regional Pharmacovigilance Centres and by GlaxoSmith-Kline, the manufacturer of bupropion, during the first 3 years of marketing of this agent. We identified the characteristics of the population to whom bupropion was prescribed from the Thales database, which contains information obtained from a representative sample of general practitioners in France. We then compared the population with SARs with the population prescribed the drug (exposed population) to identify possible risk factors such as sex, age and daily dose for the most frequent SARs.

Results: Bupropion was prescribed to 698 000 patients during the first 3 years of marketing in France. In these patients, 1682 cases of adverse reactions were reported; 28% of these involved SARs, mainly cutaneous or allergic reactions (31.2%), including angioedema and serum sickness-like reactions. Serious neurological reactions were frequent (22.5%), mostly comprising seizures; however, questioning revealed that almost half of these patients had a history of seizures or other risk factors. Of the serious neuropsychiatric adverse events reported (17.3%), suicide attempts/suicides were a cause for concern, although risk factors (history of depression, suicide attempts, etc.) were described for 66% of patients experiencing these events. Patients reporting angioedema and serum sickness-like reactions, and those involved in suicide attempts/suicides, were significantly younger than the exposed population. A dose-dependent effect was also apparent for angioedema and for seizures. Cardiovascular SARs, such as ischaemic heart disease (10.1%) or sudden death (2.3%), were very often associated with preexisting coronary artery disease induced by smoking. All these SARs occurred within a median of 12–14 days after drug initiation.

Conclusion: To ensure safer use of bupropion, health professionals must respect the strict contraindications and warnings about use of this drug in patients with a history of seizures. Seizures, angioedema and serum sickness-like reactions were the most frequently reported SARs to bupropion treatment in our study. Moreover, younger people appeared to be more at risk for cutaneous SARs generally, and younger women for angioedema in particular, perhaps because of weight-related differences in pharmacokinetics. A dose-dependent effect for angioedema and the results of skin tests were suggestive of a histamine liberation mechanism. Our analysis showed that taking more notice of the contraindications to use of bupropion could have prevented half the seizures reported to the database. The sex and age characteristics of patients with ischaemic heart disease and suicide attempts in the study population were similar to those of the French population as a whole. Whether bupropion is associated with an increase in these potential adverse effects of therapy can be determined only by epidemiological studies that take into account specific risk factors in the smoking population. Finally, the median time to onset of the SARs identified in this study suggests that prescribers should monitor patients exposed to bupropion more carefully during the first 2 weeks of treatment.


Smoking Cessation Suicide Attempt Bupropion Ischaemic Heart Disease Nicotine Replacement Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this study. The authors would like to thank all members of the network of French Regional Centres of Pharmacovigilance and AFSSAPS (Health Products French Safety Agency). The authors would also like to thank Maryse Dudu for her help in administrative organization and Dr B. Daury from GlaxoSmithKline. The authors have no conflicts of interest that are directly relevant to the content of this study.


  1. 1.
    Aronson JK, editor. Meyler's side effects of drugs. 15th ed. Oxford: Elsevier, 2006Google Scholar
  2. 2.
    Rush CR, Kollins SH, Pazzaglia PJ. Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-Amphetamine-trained humans. Exp Clin Psychopharmacol 1998 Feb; 6(1): 32–44PubMedCrossRefGoogle Scholar
  3. 3.
    Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395–401PubMedGoogle Scholar
  4. 4.
    Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195–202PubMedCrossRefGoogle Scholar
  5. 5.
    Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685–91PubMedCrossRefGoogle Scholar
  6. 6.
    Tashkin DP, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571–5PubMedCrossRefGoogle Scholar
  7. 7.
    Aubin HJ. Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs 2002; 62 Suppl. 2: 45–52PubMedCrossRefGoogle Scholar
  8. 8.
    Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991; 52(11): 450–6PubMedGoogle Scholar
  9. 9.
    Boshier A, Wilton LV, Shakir S. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol 2003; 59: 767–73PubMedCrossRefGoogle Scholar
  10. 10.
    Fagerstrom K. The epidemology of smoking: health consequences and benefits of cessation. Drugs 2002; 62 Suppl. 2: 1–9PubMedCrossRefGoogle Scholar
  11. 11.
    The Uppsala Monitorig Center. Practical pharmacovigilance [online]. Available from URL: [Accessed 2008 Sep 1]
  12. 12.
    Hazell L, Shakir S. Under-reporting of adverse drug reactions. Drug Saf 2006; 29(5): 385–96PubMedCrossRefGoogle Scholar
  13. 13.
    Kennedy D, Goldman S, Lillie R. Spontaneous reporting in the United States. In: Strom BL, editor. Pharmacoepidemiology. 3rd ed. Chichester: John Wiley and Sons, 2000: 151–74Google Scholar
  14. 14.
    Summary of product characteristics for Zyban (bupropion). GlaxoSmithKline, 9 July 2002Google Scholar
  15. 15.
    Benson E. Bupropion-induced hypersensitivity reactions. Med J Aust 2001; 174: 650–1PubMedGoogle Scholar
  16. 16.
    Stewart JJ, Berkel HJ, Parish RC, et al. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol 2001; 41(7): 770–8PubMedCrossRefGoogle Scholar
  17. 17.
    Findlay JW, Van Wyck Fleet J, Smith PG, et al. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 1981; 21(2): 127–35PubMedCrossRefGoogle Scholar
  18. 18.
    Hsyu PH, Singh A, Giargiari TD, et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997; 37: 737–43PubMedGoogle Scholar
  19. 19.
    Fays S, Trechot P, Schmutz JL, et al. Bupropion and generalized acute urticaria: eight cases. Br J Dermatol 2003; 148: 171–92CrossRefGoogle Scholar
  20. 20.
    Chiaverini C, Baldin B, Chichmanian RM, et al. Urticaire au bupropion (Zyban®): 2 cas. Ann Dermatol Venereol 2003; 130: 208–9PubMedGoogle Scholar
  21. 21.
    Loo WJ, Alexandroff A, Flanagan N. Bupropion and generalized acute urticaria: a further case [letter]. Br J Dermatol 2003; 149(3): 660PubMedCrossRefGoogle Scholar
  22. 22.
    Davis JS, Boyle MJ, Hannaford R, et al. Bupropion and serum sickness-like reaction. Med J Aust 2001; 174(9): 479–80PubMedGoogle Scholar
  23. 23.
    Kanani AS, Kalicinsky C, Warrington RJ, et al. Serum sickness-like reaction with bupropion sustained release. Can J Allergy Clin Immunol 2000; 5(1): 27–9Google Scholar
  24. 24.
    MacCollom RA, Elbe DH, Ritchie AH. Bupropion-induced serum sickness-like reaction. Ann Pharmacother 2000; 34(4): 471–3CrossRefGoogle Scholar
  25. 25.
    Muller G, Bielefeld P, Ramanantsoa M, et al. Maladie sérique et coagulopathie de consommation sous bupropion [abstract]. Rev Med Intern 2002; 23 Suppl. 2: 704sCrossRefGoogle Scholar
  26. 26.
    Ornetti P, Disson-Dautriche A, Muller G, et al. Joint symptoms in patients on bupropion therapy. Joint Bone Spine 2004; 71(6): 583–5PubMedCrossRefGoogle Scholar
  27. 27.
    Peloso PM, Baillie C. Serum sickness-like reaction with bupropion [letter]. JAMA 1999; 282(19): 1817PubMedCrossRefGoogle Scholar
  28. 28.
    Tripathi A, Greenberger PA. Bupropion hydrochloride induced serum sickness-like reaction. Ann Allergy Asthma Immunol 1999; 83: 165–6PubMedCrossRefGoogle Scholar
  29. 29.
    Weber EA, Knowles SR, Tsao S. Bupropion-induced serum sickness-like reaction [abstract no. 30]. J Allergy Clin Immunol 2001; 107(2): S331–9CrossRefGoogle Scholar
  30. 30.
    Pisani F, Oteri G, Costa C, et al. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002; 25(2): 91–110PubMedCrossRefGoogle Scholar
  31. 31.
    Dunner DL, Zisook S, Billow AA, et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998; 59(7): 366–73PubMedCrossRefGoogle Scholar
  32. 32.
    Medicines Control Agency. Zyban (bupropion hydrochloride): safety update. 29 Jul 2002 [online]. Available from URL: [Accessed 2002 Jan 20]
  33. 33.
    Réseau Sentinelles, Unité INSERM 707 [online]. Available from URL: [Accessed 2005 Mar 5]
  34. 34.
    Breslau N. Psychiatric comorbidity of smoking and nicotine dependence. Behav Genet 1995; 25: 95–101PubMedCrossRefGoogle Scholar
  35. 35.
    Hall SM, Munoz RF, Reus VI, et al. Nicotine negative affect and depression. J Consult Clin Psychol 1993; 61(5): 761–7PubMedCrossRefGoogle Scholar
  36. 36.
    Glassman AH, Covey LS, Stetner F, et al. Smoking cessation and the course of major depression: a follow-up study. Lancet 2001; 357: 1929–32PubMedCrossRefGoogle Scholar
  37. 37.
    Breslau N, Schultz LR, Johnson EO, et al. Smoking and the risk of suicidal behaviour. Arch Gen Psychiatry 2005; 62: 328–34PubMedCrossRefGoogle Scholar
  38. 38.
    Miller M, Hemenway D, Bell NS, et al. Cigarette smoking and suicide: a prospective study of 300,000 male active-duty army soldiers. Am J Epidemiol 2000; 151: 1060–3PubMedCrossRefGoogle Scholar
  39. 39.
    US Food and Drug Administration. Worsening depression and suicidality in patients being treated with antidepressant medications. Media release: 22 Mar 2004 [online]. Available from URL: [Accessed 2005 Sep 12]
  40. 40.
    Balit CR, Lynch CN, Isbister GK. Bupropion poisoning: a case series. Med J Aust 2003; 178: 61–3PubMedGoogle Scholar
  41. 41.
    Tracey JA, Cassidy N, Casey PB, et al. Bupropion (Zyban) toxicity. Ir Med J 2002; 95(1): 23–4PubMedGoogle Scholar
  42. 42.
    Shepherd G, Velez LI, Keyes DC. Intentional bupropion overdoses. J Emerg Med 2004; 27(2): 147–51PubMedCrossRefGoogle Scholar
  43. 43.
    Friel PN, Logan BK, Fligner CL. Three fatal drug overdoses involving bupropion. J Anal Toxicol 1993; 17(7): 436–8PubMedGoogle Scholar
  44. 44.
    Harris CR, Gualtieri J, Stark G. Fatal bupropion overdose. J Toxicol Clin Toxicol 1997; 35(3): 321–4PubMedCrossRefGoogle Scholar
  45. 45.
    Rohrig TP, Ray NG. Tissue distribution of bupropion in a fatal overdose. J Anal Toxicol 1992; 16(5): 343–5PubMedGoogle Scholar
  46. 46.
    Holbrook JH. Nicotine addiction. In: Harrison T, Fauci AS. Harrison's principals of internal medicine. 14th ed. New York: McGraw-Hill, Health Professions Division, 1998Google Scholar
  47. 47.
    Hubbard R, Lewis S, West J, et al. Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network. Thorax 2005; 60: 848–50PubMedCrossRefGoogle Scholar
  48. 48.
    Thun MJ, Day-Lally C, Myers DG, et al. Trends in tobacco smoking and mortality from cigarette use in Cancer Prevention Studies I (1959 through 1965) and II (1982 through 1988). In: Changes in cigarette-related disease risks and their implication for prevention and control. Smoking and tobacco control monograph 8. Bethesda (MD): U.S. Department of Health and Human Services, Public Health Service, National Institute of Health, National Cancer Institute, 1997: 305–82Google Scholar
  49. 49.
    Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003; 24(10): 946–55PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Marie-Nöelle Beyens
    • 1
  • Claire Guy
    • 1
  • Genevieve Mounier
    • 1
  • Sylvie Laporte
    • 2
  • Michel Ollagnier
    • 1
  1. 1.Regional Pharmacovigilance CentreBellevue Hospital UniversitySaint-Etienne Cedex 2France
  2. 2.Clinical Pharmacology DepartmentBellevue Hospital UniversitySaint-EtienneFrance

Personalised recommendations